// App-Quantinova.ai

POS0072 (2022) : CONSISTENT LONG-TERM GUSELKUMAB EFFICACY ACROSS PSORIATIC ARTHRITIS DOMAINS IRRESPECTIVE OF BASELINE PATIENT CHARACTERISTICS

Researchers

Presenter

  • I. Mcinnes

Principal Investigators

  • J. Tesser

  • E. Schiopu

  • J. F. Merola

  • S. D. Chakravarty

  • E. Rampakakis

  • N. Shiff

  • A. Kollmeier

  • X. L. Xu

  • M. Shawi

  • F. Lavie

  • P. Bird

  • P. J. Mease

Medical Centers

  • University of Glasgow, Glasgow, United Kingdom

  • Arizona Arthritis & Rheumatology Research, PLLC, Phoenix, United States of America

  • Michigan Medicine Rheumatology Clinic, University of Michigan Medical School, Rheumatology Internal Medicine, Ann Arbor, United States of America

  • Brigham and Women’s Hospital, Division of Rheumatology and Immunology, Harvard Medical School, Dermatology and Medicine, Boston, United States of America

  • Janssen Scientific Affairs, LLC, Immunology, Horsham, United States of America

  • Drexel University College of Medicine, Rheumatology, Philadelphia, United States of America

  • McGill University, Pediatrics, Montreal, Canada

  • JSS Medical Research, Inc, Scientific Affairs, Montreal, Canada

  • University of Saskatchewan, Community Health and Epidemiology, Saskatoon, Canada

  • Janssen Research & Development, LLC, Immunology, San Diego, CA, United States of America

  • Janssen Pharmaceutical Companies of Johnson & Johnson, Immunology Global Medical Affairs, Horsham, PA, United States of America

  • Janssen Cilag Global Medial Affairs, Global Medial Affairs, Issy les Moulineaux, France

  • University of New South Wales, Faculty of Medicine, Randwick, Australia

  • 2Swedish Medical Center/Providence St. Joseph Health and University of Washington, Rheumatology, Seattle, Washington, United States of America

Locations

  • United Kingdom

  • United States

  • Canada

  • France

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

  • Dactylitis

  • Inflammatory Arthritis

  • Psoriasis

Biomarkers

  • C reactive protein

  • Body mass index

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Amgen

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved